NCT04786457View on ClinicalTrials.gov

ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

July 9, 2021

Study Completion Date

July 9, 2021

Conditions
Dengue
Interventions
BIOLOGICAL

Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)

one subcutaneous injection of Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) at 0.5 mL of 6.5 x 10\^3 PFU/mL

Trial Locations (1)

21201

University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore

All Listed Sponsors
collaborator

United States Army Medical Materiel Development Activity

FED

collaborator

Medical Technology Enterprise Consortium (MTEC)

UNKNOWN

lead

University of Maryland, Baltimore

OTHER

NCT04786457 - ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC) | Biotech Hunter | Biotech Hunter